Paul Waymack

US Patent:

20110207724, Aug 25, 2011

Filed:

May 22, 2009

Appl. No.:

12/990724

Inventors:

Peter C. Hoyle - Lovettsville VA, US
Paul Waymack - Washington DC, US

International Classification:

A61K 31/549
A61K 31/63
A61K 31/519
A61K 31/365
A61K 31/415
A61P 9/12
A61P 29/00
A61K 31/192
A61P 7/10

US Classification:

5142235, 514471, 514249, 514473, 514406, 514571

Abstract:

An oral dosage form of a non-steroidal anti-inflammatory drug (NSAID) is rendered safer for extended or chronic use for anti-inflammatory, analgesic or antipyretic therapy by combining it with an antihypertensive drug. The antihypertensive drug acts prophylactically to inhibit or reduce NSAID-induced hypertension and by so doing the adverse cardiovascular side effects of NSAIDs, such as high blood pressure, heart attack, stroke, opththamologic complications, and death, when NSAIDs are used repetitively over an extended period of time for reducing inflammation or in pain management.

US Patent:

20110136793, Jun 9, 2011

Filed:

Feb 14, 2011

Appl. No.:

13/026741

Inventors:

Peter C. Hoyle - Lovettsville VA, US
Paul Waymack - Washington DC, US

International Classification:

A61K 31/4439
A61K 31/4418
A61K 31/165
A61K 31/5377
A61K 31/192
A61K 31/549
A61K 31/415
A61K 31/4458
A61P 29/00
A61P 25/00
A61P 9/00
A61P 9/12

US Classification:

5142235, 514338, 514356, 514620, 5142362, 514569, 514406, 514317

Abstract:

Patients which are treated with stimulants (e.g., CNS stimulants, sympathomimetic amine, or anorectic/anorexigenic), such as patients being treated for attention deficit/hyperactivity disorder or obesity, often are atrisk in developing high blood pressure. Similarly, patients which are treated with analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) over an extended period of time risk developing high blood pressure. These and other iatrogenic therapies (therapies which inadvertently cause an increase in, e.g., blood pressure) are addressed by providing the patient with one or more antihypertensive drugs, most preferably calcium channel blockers, during the treatment period. The CNS or NSAIDs can be provided separately or together with the antihypertensive drugs or as part of a combined composition. The adjunctive therapy can prevent or reduces cardiovascular disease and other complications of high blood pressure attendant with these iatrogenic therapies.

US Patent:

20160243134, Aug 25, 2016

Filed:

May 2, 2016

Appl. No.:

15/144188

Inventors:

Peter C. Hoyle - Lovettsville VA, US
Paul Waymack - Washington DC, US

Assignee:

Kitov Pharmaceuticals Ltd. - Jerusalem

International Classification:

A61K 31/635
A61K 45/06

Abstract:

An oral dosage form of a non-steroidal anti-inflammatory drug (NSAID) is rendered safer for extended or chronic use for anti-inflammatory, analgesic or antipyretic therapy by combining it with an antihypertensive drug. The antihypertensive drug acts prophylactically to inhibit or reduce NSAID-induced hypertension and by so doing the adverse cardiovascular side effects of NSAIDs, such as high blood pressure, heart attack, stroke, opththamologic complications, and death, when NSAIDs are used repetitively over an extended period of time for reducing inflammation or in pain management.

US Patent:

20160058744, Mar 3, 2016

Filed:

Nov 10, 2015

Appl. No.:

14/936739

Inventors:

Peter C. Hoyle - Lovettsville VA, US
Paul Waymack - Washington DC, US

Assignee:

JPW PCH, INC. - Lovettsville VA
KITOV PHARMACEUTICAL LTD. - Jerusalem

International Classification:

A61K 31/4422
A61K 47/12
A61K 47/26
A61K 47/36
A61K 31/635
A61K 9/00

Abstract:

Patients which are treated with stimulants (e.g., CNS stimulants, sympathomimetic amine, or anorectic/anorexigenic), such as patients being treated for attention deficit/hyperactivity disorder or obesity, often are at risk in developing high blood pressure. Similarly, patients which are treated with analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) over an extended period of time risk developing high blood pressure. These and other iatrogenic therapies (therapies which inadvertently cause an increase in, e.g., blood pressure) are addressed by providing the patient with one or more antihypertensive drugs, most preferably calcium channel blockers, during the treatment period. The CNS or NSAIDs can be provided separately or together with the antihypertensive drugs or as part of a combined composition. The adjunctive therapy can prevent or reduces cardiovascular disease and other complications of high blood pressure attendant with these iatrogenic therapies.